Home › Funds › Aisling Capital Management LP › ACRS
Aisling Capital Management LP position in ACRS
ACLARIS THERAPEUTICS INC · Health Care
Aisling Capital Management LP reported holding 434,455 shares of ACRS (ACLARIS THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$2.3M, representing 0.76% of its reported portfolio and ranking #10 among its reported holdings. Aisling Capital Management LP has disclosed ACRS holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How Aisling Capital Management LP's ACRS position evolved
Aisling Capital Management LP first disclosed a stake in ACRS in Q3 2023 at 434,455 shares (US$3.0M). Across 13 filings, Aisling Capital Management LP held the position steady without any share-count change. The most recent filing (Q3 2026) shows 434,455 shares valued at US$2.3M.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 434.45K | $2.98M | New |
| Q4 2023 | 434.45K | $456.18K | Hold |
| Q1 2024 | 434.45K | $538.72K | Hold |
| Q2 2024 | 434.45K | $477.90K | Hold |
| Q3 2024 | 434.45K | $499.62K | Hold |
| Q4 2024 | 434.45K | $1.08M | Hold |
| Q1 2025 | 434.45K | $664.72K | Hold |
| Q2 2025 | 434.45K | $616.93K | Hold |
| Q3 2025 | 434.45K | $825.47K | Hold |
| Q4 2025 | 434.45K | $1.31M | Hold |
| Q1 2026 | 434.45K | $1.63M | Hold |
| Q2 2026 | 434.45K | $2.30M | Hold |
| Q3 2026 | 434.45K | $2.29M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About ACRS and 13F data
ACRS (ACLARIS THERAPEUTICS INC) is a Health Care company. 44 other funds we track also report a position in ACRS — the largest reported positions include RA CAPITAL MANAGEMENT, L.P. (US$67.3M), BML Capital Management, LLC (US$57.6M), Deep Track Capital, LP (US$49.4M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding ACRS
- RA CAPITAL MANAGEMENT, L.P. 12.72M sh · $67.30M · Q2 2026
- BML Capital Management, LLC 10.96M sh · $57.62M · Q3 2026
- Deep Track Capital, LP 9.35M sh · $49.44M · Q2 2026
- Vivo Capital, LLC 6.69M sh · $35.21M · Q3 2026
- Frazier Life Sciences Management, L.P. 4.93M sh · $26.06M · Q2 2026
- Rock Springs Capital Management LP 4.33M sh · $22.91M · Q2 2026
- Decheng Capital LLC 4.04M sh · $21.38M · Q2 2026
- Jones Hill Capital LP 2.50M sh · $13.17M · Q3 2026
- Kalehua Capital Management LLC 1.83M sh · $9.64M · Q3 2026
- Palo Alto Investors LP 1.61M sh · $8.54M · Q2 2026
- MPM BioImpact LLC 1.04M sh · $5.51M · Q2 2026
- Aldebaran Capital, LLC 936.18K sh · $4.92M · Q3 2026
More on Aisling Capital Management LP
FAQ
How long has Aisling Capital Management LP held ACRS?
Aisling Capital Management LP has disclosed ACRS holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
What is Aisling Capital Management LP's current position in ACRS?
As of Q3 2026, Aisling Capital Management LP holds 434.45K shares of ACRS (ACLARIS THERAPEUTICS INC), valued at $2.29M, representing 0.76% of its reported portfolio and ranking #10.
Has Aisling Capital Management LP been buying or selling ACRS?
In the latest 13F filing (Q3 2026), Aisling Capital Management LP held unchanged its position in ACRS.
Which other funds hold ACRS?
Other major institutional holders of ACRS include RA CAPITAL MANAGEMENT, L.P., BML Capital Management, LLC, Deep Track Capital, LP, among 44 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.